JPH041133A - Stable oxophosphoric acid emulsion and production thereof - Google Patents
Stable oxophosphoric acid emulsion and production thereofInfo
- Publication number
- JPH041133A JPH041133A JP10040390A JP10040390A JPH041133A JP H041133 A JPH041133 A JP H041133A JP 10040390 A JP10040390 A JP 10040390A JP 10040390 A JP10040390 A JP 10040390A JP H041133 A JPH041133 A JP H041133A
- Authority
- JP
- Japan
- Prior art keywords
- water
- oxolinic acid
- aqueous solution
- acid
- stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 39
- 239000002253 acid Substances 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 39
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 32
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 18
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 18
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 18
- 239000010419 fine particle Substances 0.000 claims abstract description 13
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 12
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 6
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 5
- 229960000321 oxolinic acid Drugs 0.000 claims description 105
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 104
- 150000001875 compounds Chemical class 0.000 claims description 27
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 150000001447 alkali salts Chemical class 0.000 claims description 3
- 238000003860 storage Methods 0.000 abstract description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 8
- -1 alkali metal salt Chemical class 0.000 abstract description 6
- 238000005187 foaming Methods 0.000 abstract description 5
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 abstract description 4
- 241000861914 Plecoglossus altivelis Species 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 244000144972 livestock Species 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 241000606860 Pasteurella Species 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 206010047400 Vibrio infections Diseases 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000009372 pisciculture Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 238000003756 stirring Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 18
- 239000004094 surface-active agent Substances 0.000 description 17
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000006260 foam Substances 0.000 description 8
- 238000013112 stability test Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- WANXPWCBQXXPFK-UHFFFAOYSA-M sodium;5-ethyl-8-oxo-[1,3]dioxolo[4,5-g]quinoline-7-carboxylate Chemical compound [Na+].C1=C2N(CC)C=C(C([O-])=O)C(=O)C2=CC2=C1OCO2 WANXPWCBQXXPFK-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical group C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- HZVGIXIRNANSHU-UHFFFAOYSA-N naphthalene-1,2,3,4-tetrone Chemical compound C1=CC=C2C(=O)C(=O)C(=O)C(=O)C2=C1 HZVGIXIRNANSHU-UHFFFAOYSA-N 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、水溶性高分子化合物の水溶液中にオキソリン
酸の再結晶を微細な粒子として乳濁した乳濁液からなる
安定なオキソリン酸乳濁液およびその製造方法に関する
。Detailed Description of the Invention [Field of Industrial Application] The present invention provides a stable oxolinic acid milk, which is an emulsion in which recrystallized oxolinic acid is emulsified as fine particles in an aqueous solution of a water-soluble polymer compound. This invention relates to a suspension and a method for producing the same.
[従来の技術]
オキソリン酸は、各種の菌類に対して優れた抗菌作用を
有するキノロン系の合成抗菌剤であり、ブロイラー、豚
、牛等の畜産分野においてトリパラチフス症、パスツレ
ラ性肺炎、細菌性下痢症などの治療あるいは予防に、ま
たブリ、アユ、ウナギ等の水産分野においてブリ類結節
症、アユビブリオ病、ウナギパラコロ病等の治療あるい
は予防に使用されている。従来知られているオキソリン
酸製剤としては、散剤、アルカリ性溶液剤及び油剤があ
り、それぞれ市販されている。また、オキソリン酸の懸
濁剤としては、特開昭64−18において特定の界面活
性剤を水溶性溶剤を使用し、水性溶媒にオキソリン酸を
懸濁させたオキソリン酸懸濁剤が提案されている。[Prior Art] Oxolinic acid is a quinolone-based synthetic antibacterial agent that has excellent antibacterial effects against various fungi. It is used for the treatment or prevention of diarrheal diseases, etc., and in the field of fisheries for yellowtail, sweetfish, eel, etc., for the treatment or prevention of yellowtail nodule disease, ayuvibrio disease, eel paracoro disease, etc. Conventionally known oxolinic acid preparations include powders, alkaline solutions, and oil preparations, each of which is commercially available. Furthermore, as a suspending agent for oxolinic acid, an oxolinic acid suspending agent was proposed in JP-A-64-18 in which a specific surfactant was used in a water-soluble solvent and oxolinic acid was suspended in an aqueous solvent. There is.
[発明が解決しようとする課題]
オキソリン酸製剤が、散剤、アルカリ性溶液剤及び油剤
などとして使用されているのは、オキソリン酸が水に不
溶性であるためである。水系液薬剤とすれば、取扱が容
易で、投与による高い効果が期待される。前述の特開昭
64−18の提案もその具体的な現れの一つと言える
オキソリン酸を水系液薬剤とするための問題点としては
、水系液薬剤としての放置安定性、水稀釈安定性および
中和時の発泡性等である。放置安定性とは、オキソリン
酸の水系液薬剤を放置した場合の安定性であり、−時的
には安定化しても、放置するとオキソリン酸が沈降を起
こすことである。また、水稀釈安定性とは、オキソリン
酸の水系液薬剤を水で稀釈した場合の安定性であり、水
稀釈安定性が悪いと使用時の水の稀釈により安定性か失
われオキソリン酸が沈降してしまう、沈降が生じると有
効な濃度が保てないので実用上問題となる。[Problems to be Solved by the Invention] Oxolinic acid preparations are used as powders, alkaline solutions, oils, etc. because oxolinic acid is insoluble in water. If it is a water-based liquid drug, it will be easy to handle and high efficacy can be expected from administration. The above-mentioned proposal of JP-A-64-18 can be said to be one of the concrete manifestations of this idea, and the problems in making oxolinic acid into a water-based liquid drug include stability on storage as a water-based liquid drug, stability when diluted with water, and Watoki's foaming properties, etc. Standing stability refers to the stability of an aqueous liquid drug of oxolinic acid when it is left to stand, and means that even if it is temporarily stabilized, oxolinic acid will precipitate if left to stand. In addition, water dilution stability refers to the stability when an aqueous liquid drug of oxolinic acid is diluted with water.If the water dilution stability is poor, stability may be lost due to dilution of water during use, and oxolinic acid will precipitate. If sedimentation occurs, an effective concentration cannot be maintained, which poses a practical problem.
本発明者の研究の結果、オキソリン酸を界面活性剤によ
り水性溶媒に懸濁させるだけでは、良好な水稀釈安定性
は得られない、つまり、使用時に水で稀釈されると、界
面活性剤も稀釈され最小ミセル形成濃度(C,M、C,
)以下になるとミセルが破壊されるのでオキソリン酸の
沈降が発生する。したがって界面活性剤を使用したので
は水稀釈安定性を根本的に解決することができないこと
が解明された。As a result of the research conducted by the present inventors, it has been found that good water dilution stability cannot be obtained simply by suspending oxolinic acid in an aqueous solvent with a surfactant; that is, when diluted with water during use, the surfactant also diluted to the minimum micelle-forming concentration (C, M, C,
), micelles are destroyed and oxolinic acid precipitates. Therefore, it was found that the water dilution stability cannot be fundamentally solved by using a surfactant.
これに加えて界面活性剤の使用により生ずる中和時の発
泡の問題がある。酸による中和時に均一に中和を行うた
めには撹拌する必要があるが、このとき界面活性剤を使
用すると多量の泡が発生し、均一な中和反応を阻害し、
泡による表面積の増大のため、泡末状態での凝固が起り
粗粒子が生成する重大な欠点がある。In addition to this, there is the problem of foaming during neutralization caused by the use of surfactants. Stirring is necessary for uniform neutralization during acid neutralization, but if a surfactant is used at this time, a large amount of foam will be generated, which will inhibit the uniform neutralization reaction.
Due to the increase in surface area due to the foam, there is a serious drawback that coagulation occurs at the end of the foam and coarse particles are produced.
さらに、放1安定性においても界面活性剤では粒子を充
分に安定化出来ず、放置中に発生するオキソリン酸の再
結晶や粒子の固着も間Uの一つである。Furthermore, even in terms of stability, surfactants cannot sufficiently stabilize particles, and recrystallization of oxolinic acid and fixation of particles that occur during standing are also problems.
[課題を解決した手段および作用]
本発明者は、オキソリン酸の水系液薬剤における問題点
を解決すべく種々研究を重ねた結果、水溶性高分子化合
物の水溶液中にオキソリン酸の再結晶を微細な粒子とし
て乳濁した乳濁液は水稀釈安定性、放置安定性に優れて
おり、また、オキソリン酸アルカリ塩と水溶性高分子化
合物を溶解している水溶液に酸を加え、水溶液を中和す
ることによりオキソリン酸を再結晶させて、水溶性高分
子化合物の水溶液中に安定な微細な粒子として乳濁させ
ることにより発泡を生ずることなく、上記の安定な乳濁
液を製造することができる新知見を得て、本発明を完成
しな。[Means for Solving the Problems and Effects] As a result of repeated research in order to solve the problems in aqueous liquid medicines containing oxolinic acid, the present inventors have discovered that fine recrystallization of oxolinic acid can be carried out in an aqueous solution of a water-soluble polymer compound. The emulsion, which is formed as particles, has excellent water dilution stability and storage stability.Also, it is possible to neutralize the aqueous solution by adding an acid to an aqueous solution in which an alkali oxolinic acid salt and a water-soluble polymer compound are dissolved. By recrystallizing oxolinic acid and emulsifying it as stable fine particles in an aqueous solution of a water-soluble polymer compound, the above-mentioned stable emulsion can be produced without foaming. Obtain new knowledge and complete the present invention.
本発明は、
「 1.水溶性高分子化合物の水溶液中にオキソリン酸
の再結晶を微細な粒子として乳濁した安定なオキソリン
酸乳濁液。The present invention is characterized by: 1. A stable oxolinic acid emulsion in which recrystallized oxolinic acid is emulsified as fine particles in an aqueous solution of a water-soluble polymer compound.
2、水溶性高分子化合物が水溶性のセルロース誘導体で
ある請求項1に記載された、オキソリン酸乳濁液。2. The oxolinic acid emulsion according to claim 1, wherein the water-soluble polymer compound is a water-soluble cellulose derivative.
3、水溶性高分子化合物が水溶性のヒドロキシプロピル
セルロースおよびまたはヒドロキシエチルセルロースで
ある請求項1または2に記載されたオキソリン酸乳濁液
。3. The oxolinic acid emulsion according to claim 1 or 2, wherein the water-soluble polymer compound is water-soluble hydroxypropyl cellulose and/or hydroxyethyl cellulose.
4、オキソリン酸アルカリ塩と水溶性高分子化合物を溶
解している水溶液に酸を加え、水溶液を中和することに
よりオキソリン酸を再結晶し、水溶性高分子化合物の水
溶液中に安定な微細な粒子として乳濁させることを特徴
とする安定なオキソリン酸乳濁液の製造方法。4. Add acid to an aqueous solution in which an alkali salt of oxolinic acid and a water-soluble polymer compound are dissolved, and recrystallize the oxolinic acid by neutralizing the aqueous solution to form stable fine particles in the aqueous solution of the water-soluble polymer compound. A method for producing a stable oxolinic acid emulsion, characterized by emulsifying it as particles.
5、水溶性高分子化合物が水溶性のセルロース誘導体で
ある請求項4に記載された安定なオキソリン酸乳濁液の
製造方法。5. The method for producing a stable oxolinic acid emulsion according to claim 4, wherein the water-soluble polymer compound is a water-soluble cellulose derivative.
6.水溶性高分子化合物が水溶性のヒドロキシプロピル
セルロースおよびまたはヒドロキシエチルセルロースで
ある請求項4または5に記載された安定なオキソリン酸
乳濁液の製造方法、」に関する。6. 6. The method for producing a stable oxolinic acid emulsion according to claim 4 or 5, wherein the water-soluble polymer compound is water-soluble hydroxypropyl cellulose and/or hydroxyethyl cellulose.
本発明で使用される水溶性高分子化合物としては、アラ
ビアゴム、水溶性の加工澱粉、水溶性セルロース誘導体
、ポリビニルアルコール、ポリビニルピロリドン、など
が挙げられ、これらを単独または併用して使用すること
ができる0本発明のオキソリン酸乳濁液が主として畜産
、水産等の分野の生物に適用されることから理解される
ように、水溶性高分子化合物として食品に使用が認めら
れている水溶性高分子化合物を選択することが好ましい
ことは当然である。Examples of the water-soluble polymer compound used in the present invention include gum arabic, water-soluble modified starch, water-soluble cellulose derivatives, polyvinyl alcohol, polyvinylpyrrolidone, etc., and these may be used alone or in combination. As can be understood from the fact that the oxolinic acid emulsion of the present invention is mainly applied to organisms in the fields of livestock and fisheries, it is a water-soluble polymer that is approved for use in foods as a water-soluble polymer compound. It goes without saying that the choice of compounds is preferred.
水溶性高分子化合物のなかでも、放置安定性が良好な水
溶性セルロース誘導体が好ましい、水溶性セルロース誘
導体としては、メチルセルロース、エチルセルロース、
カルボキシメチルセルロース、カルボキシエチルセルロ
ース、ヒドロキシエチルセルロース、ヒドロキシプロピ
ルセルロース、などが使用され、これらを単独または併
用して使用することかできる。Among water-soluble polymer compounds, water-soluble cellulose derivatives having good storage stability are preferred. Examples of water-soluble cellulose derivatives include methylcellulose, ethylcellulose,
Carboxymethyl cellulose, carboxyethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc. are used, and these can be used alone or in combination.
本発明は、オキソリン酸水溶液を酸により中和してオキ
ソリン酸を再結晶させるので、これらの水溶性高分子の
中でも酸により水溶性や粘度に影響を受けないものが好
ましい。In the present invention, oxolinic acid is recrystallized by neutralizing the oxolinic acid aqueous solution with acid, so among these water-soluble polymers, those whose water solubility and viscosity are not affected by acid are preferred.
とくにヒドロキシプロピルセルロースとヒドロキシエチ
ルセルロースが良好な作用、効果を奏する。In particular, hydroxypropylcellulose and hydroxyethylcellulose exhibit good action and effects.
一方力ルボキシメチルセルロース等は酸の影響を受ける
ので単独の使用はあまり好ましい結果を与えない。On the other hand, since carboxymethyl cellulose and the like are affected by acids, their use alone does not give very favorable results.
また、本発明で使用される酸としては、無m酸、有I!
laなどでアルカリを中和することのできる酸であれば
いずれでも使用することができ2種以上の併用もできる
。その中でも特に、塩酸が好ましい。In addition, the acids used in the present invention include non-acids, I!
Any acid that can neutralize an alkali, such as la, can be used, and two or more types can be used in combination. Among these, hydrochloric acid is particularly preferred.
安定なオキソリン酸乳濁液は、オキソリン酸アルカリ塩
と水溶性高分子化合物を溶解している水溶液に酸を加え
、水溶液を中和することによりオキソリン酸を再結晶さ
せ、水溶性高分子化合物の水溶液中に安定な微細な粒子
として乳濁させることによって得られる。A stable oxolinic acid emulsion is produced by adding an acid to an aqueous solution containing an alkali salt of oxolinic acid and a water-soluble polymer compound, and recrystallizing the oxolinic acid by neutralizing the aqueous solution. It is obtained by emulsifying stable fine particles in an aqueous solution.
本発明のオキソリン酸乳濁液が、なぜ放置安定性および
水稀釈安定性に優れているかはまだ理論的には充分に明
らかではないところもあるが、本発明者は本発明の乳濁
液がオキソリン酸粉末を界面活性剤により水性溶媒に懸
濁させただけの懸濁液とは、オキソリン酸の微細な粒子
の状態が明らかに興なっていることによるものと考えて
いる。Although it is still not completely clear theoretically why the oxolinic acid emulsion of the present invention has excellent storage stability and water dilution stability, the present inventors believe that the oxolinic acid emulsion of the present invention It is believed that the suspension, which is simply a suspension of oxolinic acid powder in an aqueous solvent using a surfactant, is due to the fact that the state of fine particles of oxolinic acid has clearly developed.
つまり、本発明のオキソリン酸乳濁液は、オキソリン酸
が再結晶して微細な粒子として分散系に生成したもので
あること、および生成した時点で直ちに水溶性高分子に
より安定化されていることが放置安定性および水稀釈安
定性の優れている理由の一つと考えている。In other words, the oxolinic acid emulsion of the present invention is produced by recrystallizing oxolinic acid as fine particles in a dispersion system, and is immediately stabilized by a water-soluble polymer at the time of production. This is considered to be one of the reasons for its excellent storage stability and water dilution stability.
中和により再結晶したオキソリン酸微粒の表面に付着し
た水溶性高分子は保護コロイド的に作用し、吸着等によ
り再結晶粒子表面に存在し、稀釈によっても影響を受け
ず、後添加とは興なる性能を示すためと考えられる。し
たがって界面活性剤のような稀釈時のミセルの破壊によ
る沈降現象は発生しない。The water-soluble polymer attached to the surface of the oxolinic acid fine particles recrystallized by neutralization acts like a protective colloid, exists on the surface of the recrystallized particle by adsorption, is not affected by dilution, and is not affected by post-addition. This is thought to be due to the fact that it shows a certain performance. Therefore, unlike surfactants, sedimentation due to destruction of micelles during dilution does not occur.
これに対して、界面活性剤による安定化は界面活性剤の
量にも大きな影響があり、前述のように水に稀釈すると
最小ミセル形成濃度(C,M、C。On the other hand, stabilization by surfactants has a large effect on the amount of surfactant, and as mentioned above, when diluted with water, the minimum micelle formation concentration (C, M, C) is reached.
)以下になるとミセルが破壊され界面活性剤による安定
が失われオキソリン酸が沈降してしまうものと考えてい
る。) or below, the micelles are destroyed, the stability provided by the surfactant is lost, and oxolinic acid is thought to precipitate.
さらに放置安定性についても、オキソリン酸粉末を界面
活性剤により水性溶媒に懸濁させただけの懸濁液では、
オキソリン酸の粒子を完全に安定化することができず、
そのためオキソリン酸の再結晶化や粒子の固着が起こり
、優れた放置安定性が得られないものとおもわれる。Furthermore, regarding storage stability, a suspension of oxolinic acid powder suspended in an aqueous solvent using a surfactant has no
It is not possible to completely stabilize the particles of oxolinic acid,
Therefore, it is thought that recrystallization of oxolinic acid and fixation of particles occur, making it impossible to obtain excellent storage stability.
本発明者は、水溶性高分子化合物の代わりに種々の界面
活性剤や種々の水溶性化合物を使用して実験検討したが
、水溶液を中和することによりオキソリン酸を再結晶さ
せることはできても、結晶が沈降してしまい安定化する
ことができなかったり、あるいは再結晶を微細な粒子と
して安定化することができずに大きな結晶として析出し
てしまった。ただ、水溶性高分子化合物の水溶液中で中
和した場合にのみ安定なオキソリン酸乳濁液が得られた
のである。The present inventor conducted experiments using various surfactants and various water-soluble compounds instead of water-soluble polymer compounds, but it was not possible to recrystallize oxolinic acid by neutralizing the aqueous solution. Also, the crystals precipitated and could not be stabilized, or the recrystallization could not be stabilized as fine particles and precipitated as large crystals. However, a stable oxolinic acid emulsion was obtained only when neutralized in an aqueous solution of a water-soluble polymer compound.
本発明において、水溶性高分子化合物の使用量は、得ら
れるオキソリン酸乳濁液中のオキソリン酸の量によって
も興なり特別限定されないが、水溶性高分子化合物の濃
度が得られたオキソリン酸乳濁液中で0.5〜5重量%
であることが好ましい。In the present invention, the amount of the water-soluble polymer compound to be used depends on the amount of oxolinic acid in the obtained oxolinic acid emulsion and is not particularly limited. 0.5-5% by weight in suspension
It is preferable that
本発明において、オキソリン酸の量は乳濁液中1〜10
重量%であることが好ましい。In the present invention, the amount of oxolinic acid in the emulsion is between 1 and 10
Preferably, it is % by weight.
使用時に適宜稀釈して使用するのがこの種薬剤の通例で
あることからみてできるだけ濃度の高いことが望ましい
が、一方、安定性の問題もあり、上記範囲が最適である
。Since it is customary for this type of drug to be diluted appropriately before use, it is desirable that the concentration be as high as possible, but on the other hand, there is also the problem of stability, so the above range is optimal.
本発明のオキソリン酸乳濁液には、安息香酸ナトリウム
やパラオキシ安息香酸メチル等のごとき防腐剤、着色剤
、香料等を所望により含有させることができる。The oxolinic acid emulsion of the present invention may contain preservatives such as sodium benzoate and methyl paraoxybenzoate, coloring agents, fragrances, and the like, if desired.
次に実施例と比較例を挙げて本発明を説明する。Next, the present invention will be explained with reference to Examples and Comparative Examples.
実施例1
ヒドロキシプロピルセルロース6重量部を撹拌している
水94重量部中に徐々に加えて溶解し、6%ヒドロキシ
プロピルセルロース水溶液を得た。Example 1 6 parts by weight of hydroxypropylcellulose was gradually added and dissolved in 94 parts by weight of water while stirring to obtain a 6% aqueous hydroxypropylcellulose solution.
混合槽に6%ヒドロキシプロピルセルロース水溶液42
重量部を仕込み、粉末状のオキソリン酸5重量部を仕込
み、撹拌して均一に分散させた。6% hydroxypropylcellulose aqueous solution 42 in the mixing tank
5 parts by weight of powdered oxolinic acid were added and stirred to uniformly disperse the mixture.
水酸化ナトリウム10重量%水溶液9重量部を加えて、
撹拌してオキソリン酸5重量部を完全に溶解した。Adding 9 parts by weight of a 10% by weight aqueous solution of sodium hydroxide,
The mixture was stirred to completely dissolve 5 parts by weight of oxolinic acid.
ヒドロキシプロピルセルロースとオキソリン酸ナトリウ
ム塩を溶解した水溶液を強く撹拌しながら塩fi1.9
11量%水溶液44f!量部を徐々に滴下してEIHを
約7に調製し、安定なオキソリン酸乳濁液を得た。While vigorously stirring an aqueous solution containing hydroxypropylcellulose and sodium oxolinate, the salt fi1.9
11% aqueous solution 44f! The EIH was adjusted to about 7 by gradually dropping a certain amount to obtain a stable oxolinic acid emulsion.
得られたオキソリン酸乳濁液のオキソリン酸の濃度は約
5重量%、しドロキシプロピルセルロースの濃度は約2
.5重量%であった。The concentration of oxolinic acid in the obtained oxolinic acid emulsion was approximately 5% by weight, and the concentration of droxypropyl cellulose was approximately 2% by weight.
.. It was 5% by weight.
実施例2
しドロキシエチルセルロース8重量部を撹拌している水
94重量部中に徐々に加えて溶解し、8%ヒドロキシエ
チルセルロース水溶液を得た。Example 2 8 parts by weight of hydroxyethyl cellulose were gradually added and dissolved in 94 parts by weight of water while stirring to obtain an 8% aqueous hydroxyethyl cellulose solution.
混合槽に8%ヒドロキシエチルセルロース水溶液42重
量部を仕込み、粉末状のオキソリン酸5重量部を仕込み
、撹拌して均一に分散させた。A mixing tank was charged with 42 parts by weight of an 8% hydroxyethyl cellulose aqueous solution, and 5 parts by weight of powdered oxolinic acid, and stirred to uniformly disperse the mixture.
水酸化ナトリウム10重量%水溶液9重量部を知見て、
撹拌してオキソリンに5重量部を完全に溶解した。Knowing that 9 parts by weight of a 10% by weight aqueous solution of sodium hydroxide,
With stirring, 5 parts by weight of the oxoline was completely dissolved.
ヒドロキシエチルセルロースとオキソリン酸ナトリウム
塩を溶解した水溶液を強く撹拌しながら塩酸1.9重量
%水溶液44重量部を徐々に滴下してElMを約7に調
製し、安定なオキソリン酸乳濁液を得た。44 parts by weight of a 1.9% by weight aqueous solution of hydrochloric acid was gradually added dropwise to an aqueous solution in which hydroxyethylcellulose and sodium oxolinate were dissolved with strong stirring to adjust the ElM to about 7 to obtain a stable oxolinic acid emulsion. .
得られたオキソリン酸乳濁液のオキソリン酸の濃度は約
5重量%、ヒドロキシエチルセルロースの濃度は約3.
4重量%であった。The concentration of oxolinic acid in the obtained oxolinic acid emulsion was about 5% by weight, and the concentration of hydroxyethylcellulose was about 3.5% by weight.
It was 4% by weight.
実施例3
粉末状のオキソリン酸5重量部を水・40重量部に撹拌
しながら加え均一に分散した。水酸化ナトリウム10j
iJ1%水溶液9f!量部を加えて、撹拌してオキソリ
ン酸51jL量部を完全に溶解した。Example 3 5 parts by weight of powdered oxolinic acid was added to 40 parts by weight of water with stirring and uniformly dispersed. Sodium hydroxide 10j
iJ 1% aqueous solution 9f! 51 parts of oxolinic acid was added and stirred to completely dissolve 51 parts of oxolinic acid.
オキソリン酸ナトリウム塩を溶解した水溶液54重量部
を撹拌しながらヒドロキシプロピルセルロース粉末21
jL量部を徐々に加えた。添加終了後1時間撹拌を続は
分散、溶解しな、さらに−日装置してヒドロキシプロピ
ルセルロースを完全に溶解した。While stirring 54 parts by weight of an aqueous solution in which sodium oxophosphate was dissolved, 21 parts of hydroxypropyl cellulose powder was added.
jL parts were added gradually. After the addition was completed, the mixture was stirred for 1 hour for dispersion and dissolution, and then continued for another day to completely dissolve the hydroxypropyl cellulose.
ヒドロキシプロピルセルロースとオキソリン酸ナトリウ
ム塩を溶解した水溶液を強く撹拌しながら塩61.9重
量%水溶液44重量部を徐々に滴下してpHを約7に調
製し、安定なオキソリン酸乳濁液を得た。While strongly stirring an aqueous solution in which hydroxypropyl cellulose and oxolinic acid sodium salt were dissolved, 44 parts by weight of a 61.9% salt aqueous solution was gradually added dropwise to adjust the pH to about 7 to obtain a stable oxolinic acid emulsion. Ta.
得られたオキソリン酸乳濁液のオキソリン酸の濃度は約
5重量%、ヒドロキシプロピルセルロースの濃度は約2
,5重量%であった。The concentration of oxolinic acid in the obtained oxolinic acid emulsion was approximately 5% by weight, and the concentration of hydroxypropyl cellulose was approximately 2% by weight.
, 5% by weight.
比較例1
実施例1において使用したヒドロキシブ口ビルセルロー
スの代わりにポリオキシエチレン硬化しマシ油を使用し
た以外は、実施例1と同様にしてオキソリン酸懸濁液を
得た。Comparative Example 1 An oxolinic acid suspension was obtained in the same manner as in Example 1, except that polyoxyethylene hardened mustard oil was used instead of the hydroxybutylene cellulose used in Example 1.
比較例2
実施例1において、6%ヒドロキシプロピルセルロース
水溶液42重量部に粉末状のオキソリン酸5重量部を撹
拌して均一に分散させた液をボールミルにより24時間
懸濁、粉砕してオキソリン酸懸濁液を得た。Comparative Example 2 In Example 1, 5 parts by weight of powdered oxolinic acid was stirred and uniformly dispersed in 42 parts by weight of a 6% hydroxypropylcellulose aqueous solution, which was then suspended for 24 hours using a ball mill and pulverized to obtain an oxolinic acid suspension. A cloudy liquid was obtained.
比較例3
界面活性剤を配合した市販のオキソリン酸懸濁液を用い
た。Comparative Example 3 A commercially available oxolinic acid suspension containing a surfactant was used.
比較例4
粉末状のオキソリン酸5重量部を水40重量部に撹拌し
ながら加え均一に分散した。水酸化ナトリウム10重量
%水溶液9重量部を加えて、撹拌してオキソリン酸5重
量部を完全に溶解した。Comparative Example 4 5 parts by weight of powdered oxolinic acid was added to 40 parts by weight of water with stirring and uniformly dispersed. 9 parts by weight of a 10% by weight aqueous solution of sodium hydroxide was added and stirred to completely dissolve 5 parts by weight of oxolinic acid.
このオキソリン酸ナトリウム塩を溶解した水溶液を強く
撹拌しなから塩a1.9重量%水溶液44重量部を徐々
に滴下してI)Hを約7に調製し、オキソリン酸再結晶
の微粉末の懸濁液を得た。この懸濁液は撹拌を止めると
オキソリン酸の微粉末が沈降した。While strongly stirring the aqueous solution in which the sodium oxolinic acid salt was dissolved, 44 parts by weight of a 1.9% by weight aqueous solution of salt a was gradually added dropwise to adjust I)H to about 7, and a fine powder of recrystallized oxolinic acid was suspended. A cloudy liquid was obtained. When stirring of this suspension was stopped, fine powder of oxolinic acid precipitated.
上記の懸濁液を強く撹拌しながら、ヒドロキシグロピル
セルロース粉末2重量部を徐々に加えた。While vigorously stirring the above suspension, 2 parts by weight of hydroxyglopyl cellulose powder was gradually added.
添加終了後1時間撹拌を続は分散、溶解した。さらに−
日装置してヒドロキシプロピルセルロースを完全に溶解
し、オキソリン酸懸濁液をえた。After the addition was completed, stirring was continued for 1 hour to further disperse and dissolve. Furthermore-
The hydroxypropylcellulose was completely dissolved in a day-long apparatus to obtain an oxolinic acid suspension.
試験例1
実施例で得なオキソリン酸乳濁液および比較例で得たオ
キソリン酸懸濁液について、下記の放置安定性試験およ
び水稀釈安定性試験を行なった。Test Example 1 The following storage stability test and water dilution stability test were conducted on the oxolinic acid emulsion obtained in the example and the oxolinic acid suspension obtained in the comparative example.
試験結果は、第−表の通りであった。The test results were as shown in Table 1.
放置安定性試験
試料100 mlを100 mlのメスシリンダーに入
れ、上部を密閉し、3ケ月間放置し、試料を観察した。Storage stability test 100 ml of the sample was placed in a 100 ml measuring cylinder, the top was sealed, and the cylinder was left to stand for 3 months and the sample was observed.
水稀釈安定性試験
試料10srを水3000ccに撹拌しながら加え、3
00倍の水稀釈液とし、水稀釈液100m1を100m
1のメスシリンダーに入れ、上部を密閉し、1日数!後
の安定性を観察した。Add 10sr of water dilution stability test sample to 3000cc of water with stirring,
00 times diluted with water, 100ml of water diluted with 100ml
Pour into a graduated cylinder and seal the top for 1 day! The subsequent stability was observed.
(以下余白)
[註]
放置安定性試験については3ケ月放置後の試料を撹拌し
て製造直後(放1前)の試料と比較した。(Margins below) [Note] Regarding the storage stability test, the sample after being left for 3 months was stirred and compared with the sample immediately after production (1 day before release).
水稀釈安定性試験については1日放置後の試料を撹拌し
て水稀釈直後(放置前)の試料と比較した。Regarding the water dilution stability test, the sample after being left for one day was stirred and compared with the sample immediately after being diluted with water (before being left to stand).
良: 簡単な撹拌により放置前の試料と同じ状態になっ
た。Good: After simple stirring, the sample became in the same condition as before being left.
可: 強く撹拌することにより放置前の試料と同じ状態
になった。Fair: By stirring strongly, the state became the same as the sample before being left.
慝: 強く撹拌しても、撹拌を止めると沈澱物が認めら
れ、放置前の試料と同じ状態にはならなかった。杆:Even if the sample was stirred strongly, a precipitate was observed when the stirring was stopped, and the sample was not in the same state as before it was left standing.
上澄み((DI):安定性試験後にオキソリン酸粒子の
沈降によって生ずる、上部の透明
層をメスシリンダーの容積で表す。Supernatant ((DI): The upper transparent layer resulting from the settling of the oxolinic acid particles after the stability test is expressed in graduated cylinder volume.
沈澱物(ml):安定性試験後にオキソリン酸粒子の沈
降によって生ずる、下部の懸濁
液より濃くなった部分をメスシリン
ダーの容積で表す。Sediment (ml): The thicker part of the lower suspension resulting from the settling of the oxolinic acid particles after the stability test is expressed as the volume of the graduated cylinder.
く評価〉
本発明の実施例のオキソリン酸懸濁液は長期保存しても
変わること゛はなく、投与のなめ水で稀釈したものは1
日後も使用出来る。しかし、比較例のオキソリン酸懸濁
液は長期保存することが出来ず、特に投与のため水で稀
釈したものは1日後に使用することが出来ないくオキソ
リン酸が沈降して正確な量を投与できない)、そのため
使用する量だけ水で稀釈し、短い時間内に投与しなけれ
ばならない、また使用後残った場合、オキソリン酸が沈
降するので、放置しておくことができず、使用上不都合
である。Evaluation: The oxolinic acid suspension of the example of the present invention does not change even after long-term storage, and the oxolinic acid suspension of the example of the present invention does not change even after long-term storage.
It can be used even after a day. However, the oxolinic acid suspension of the comparative example cannot be stored for a long period of time, and especially those diluted with water for administration cannot be used after one day, and the oxolinic acid will precipitate, making it difficult to administer the correct amount. Therefore, it is necessary to dilute the amount to be used with water and administer it within a short period of time, and if it remains after use, the oxolinic acid will precipitate, so it cannot be left unattended, making it inconvenient to use. be.
試験例2
実施例1で得たオキソリン酸乳濁液および比較例2で得
たオキソリン酸懸濁液について、採卵鶏(3羽)に体重
1眩当たりオキソリン酸として1011g相当量を強制
経口投与した。Test Example 2 The oxolinic acid emulsion obtained in Example 1 and the oxolinic acid suspension obtained in Comparative Example 2 were forcibly administered orally to egg-laying hens (3 birds) in an amount equivalent to 1011 g of oxolinic acid per 1 body weight. .
投与後、2.4.6.10時間目に採血し血漿中のオキ
ソリン酸濃度を測定した。Blood was collected at 2.4.6.10 hours after administration, and the oxolinic acid concentration in plasma was measured.
試験結果は、第二表の通りであった。The test results were as shown in Table 2.
!−二=−勇
く評価〉
本発明の実施例はオキソリン酸の血液中の高濃度の持続
性が良好で抗菌効果が優れていることが理解される。! -2 = - Strong evaluation> It is understood that the examples of the present invention have good sustainability of high concentration of oxolinic acid in blood and excellent antibacterial effect.
比較例5
実施例1のヒドロキシプロピルセルロース使用量6重量
部を3重量部とし界面活性剤であるポリオキシエチレン
ソルビタン脂肪酸エステル3重量部を併用した以外は実
施例1と同様にしてオキソリン酸懸濁液を得た。この比
較例は水溶性セルロース誘導体と界面活性剤を併用した
例である。Comparative Example 5 Oxolinic acid suspension was prepared in the same manner as in Example 1 except that the amount of hydroxypropyl cellulose used in Example 1 was 3 parts by weight and 3 parts by weight of polyoxyethylene sorbitan fatty acid ester as a surfactant was used in combination. I got the liquid. This comparative example is an example in which a water-soluble cellulose derivative and a surfactant were used together.
試験例3
実施例1と比較例5について中和時の泡の生成について
比較した。Test Example 3 Example 1 and Comparative Example 5 were compared in terms of foam generation during neutralization.
(1)塩酸水溶液による中和前のオキソリン酸ナトリウ
ム塩を溶解した水溶液の撹拌について実施例1では、撹
拌軸の回りにわずかに痕跡程度の泡の生成がみられたに
過ぎず、塩酸水溶液を液面に直接滴下することができた
。(1) Stirring of an aqueous solution of oxolinic acid sodium salt before neutralization with an aqueous hydrochloric acid solution In Example 1, only traces of bubbles were observed around the stirring shaft; It was possible to drip directly onto the liquid surface.
比較例5では、泡の生成が多量であり、液面は泡で覆わ
れてしまった。In Comparative Example 5, a large amount of foam was generated, and the liquid surface was covered with foam.
(2)オキソリン酸乳濁液の泡について実施例1のオキ
ソリン酸乳濁液の製造直後の痕跡程度の泡は、1日放置
後に完全に消えた。(2) Regarding the foam of the oxolinic acid emulsion The traces of foam immediately after the production of the oxolinic acid emulsion of Example 1 completely disappeared after being left for one day.
比較例5では、製造直後、液面より7.5C11〜10
■の泡が生成しており、1日放置後にも泡は7.5■の
ままであった。In Comparative Example 5, 7.5C11-10 from the liquid level immediately after production.
Bubbles of 2 were formed, and even after being left for one day, the bubbles remained at 7.5 .
[効 果]
本発明のオキソリン酸乳濁液は前述のように優れた放置
安定効果と、水稀釈安定効果及び製遺時の非発泡効果を
奏する。[Effects] As mentioned above, the oxolinic acid emulsion of the present invention exhibits excellent storage stability effects, water dilution stabilization effects, and non-foaming effects during manufacture.
Claims (1)
結晶を微細な粒子として乳濁した安定なオキソリン酸乳
濁液。 2、水溶性高分子化合物が水溶性のセルロース誘導体で
ある請求項1に記載された、オキソリン酸乳濁液。 3、水溶性高分子化合物が水溶性のヒドロキシプロピル
セルロースおよびまたはヒドロキシエチルセルロースで
ある請求項1または2に記載されたオキソリン酸乳濁液
。 4、オキソリン酸アルカリ塩と水溶性高分子化合物を溶
解している水溶液に酸を加え、水溶液を中和することに
よりオキソリン酸を再結晶し、水溶性高分子化合物の水
溶液中に安定な微細な粒子として乳濁させることを特徴
とする安定なオキソリン酸乳濁液の製造方法。 5、水溶性高分子化合物が水溶性のセルロース誘導体で
ある請求項4に記載された安定なオキソリン酸乳濁液の
製造方法。 6、水溶性高分子化合物が水溶性のヒドロキシプロピル
セルロースおよびまたはヒドロキシエチルセルロースで
ある請求項4または5に記載された安定なオキソリン酸
乳濁液の製造方法。[Claims] 1. A stable oxolinic acid emulsion in which recrystallized oxolinic acid is emulsified as fine particles in an aqueous solution of a water-soluble polymer compound. 2. The oxolinic acid emulsion according to claim 1, wherein the water-soluble polymer compound is a water-soluble cellulose derivative. 3. The oxolinic acid emulsion according to claim 1 or 2, wherein the water-soluble polymer compound is water-soluble hydroxypropyl cellulose and/or hydroxyethyl cellulose. 4. Add acid to an aqueous solution in which an alkali salt of oxolinic acid and a water-soluble polymer compound are dissolved, and recrystallize the oxolinic acid by neutralizing the aqueous solution to form stable fine particles in the aqueous solution of the water-soluble polymer compound. A method for producing a stable oxolinic acid emulsion, characterized by emulsifying it as particles. 5. The method for producing a stable oxolinic acid emulsion according to claim 4, wherein the water-soluble polymer compound is a water-soluble cellulose derivative. 6. The method for producing a stable oxolinic acid emulsion according to claim 4 or 5, wherein the water-soluble polymer compound is water-soluble hydroxypropyl cellulose and/or hydroxyethyl cellulose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10040390A JPH041133A (en) | 1990-04-18 | 1990-04-18 | Stable oxophosphoric acid emulsion and production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10040390A JPH041133A (en) | 1990-04-18 | 1990-04-18 | Stable oxophosphoric acid emulsion and production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH041133A true JPH041133A (en) | 1992-01-06 |
Family
ID=14273017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10040390A Pending JPH041133A (en) | 1990-04-18 | 1990-04-18 | Stable oxophosphoric acid emulsion and production thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH041133A (en) |
-
1990
- 1990-04-18 JP JP10040390A patent/JPH041133A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4143130A (en) | Method for treating kidney stones | |
| US4321277A (en) | Germicidal use of compositions containing certain quaternary ammonium compounds | |
| KR20090073248A (en) | Levamifeed-containing aqueous suspension and preparation method thereof | |
| US6410543B1 (en) | Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution | |
| JP3523260B2 (en) | Fenbendazole formulation | |
| DE60033044T2 (en) | COMPOSITION OF MORPHINE METHANSULPHONATE AND CHITOSAN FOR NASAL ADMINISTRATION | |
| US5874103A (en) | Ionophore antibiotic formulations | |
| CA2388325C (en) | Ciclesonide-containing aqueous pharmaceutical composition | |
| AU610464B2 (en) | Germicidal composition | |
| JPH041133A (en) | Stable oxophosphoric acid emulsion and production thereof | |
| WO1992017174A1 (en) | Process for preparing aqueous suspension | |
| TW434028B (en) | Ionophore antibiotic formulations | |
| JPH0789857A (en) | Aqueous supension solution | |
| JP2002518348A (en) | Liquid containing prostaglandin and benzyl alcohol | |
| JP2985714B2 (en) | Antimicrobial composition | |
| CA2076558A1 (en) | Pharmaceutical compositions containing bradykinin antagonists for local use on the nose and eyes | |
| US6800631B2 (en) | Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution | |
| JPH0930968A (en) | Eye drops for the treatment of glaucoma and ocular hypertension | |
| JPS59110655A (en) | Manufacture of p-butoxyphenylacetylhydroxamic acid | |
| CA2225741C (en) | Ionophore antibiotic formulations | |
| JP3452375B2 (en) | Antimicrobial liquid for animals | |
| AU741614B2 (en) | Ionophore antibiotic formulations | |
| KR930001807B1 (en) | Suspension of oxolinic acid | |
| CN104586762A (en) | Rebamipide-containing drug composition and preparation method thereof | |
| AU774516B2 (en) | Ionophore antibiotic formulations |